I had a feeling I did not articulate that question
Post# of 148172
(Total Views: 838)
Posted On: 06/06/2020 2:41:19 AM
I had a feeling I did not articulate that question very well -- or the reasoning behind it. So, allow me take another stab at it.
In the two posts linked directly below, iHub board member Rockleo, who I believe might be a doctor and may have experience running clinical trials, has stated two facts:
Links
https://investorshub.advfn.com/boards/read_ms...=156094612
https://investorshub.advfn.com/boards/read_ms...=156094867
Facts
1. Dr. BP can view the labs. Dr. BP can absolutely can tell which patients are getting what.
My Comment: This is not new information and many of us (myself included) have authored posts indicating that Dr. BP very likely knows exactly which trial participants are receiving leronlimab -- and which are not.
2. As sponsor, Dr. NP is able to see the clinical status of the patients and their corresponding labs. And he is able to confirm if good or great results are being translated into clinical improvements in the patients.
My Comment: This is part I was not formerly aware of -- and it was specifically what I was asking about in my first post. I did not know that Dr. NP (or anyone else for that matter) was in a position to cross-reference each participant's labs -- against their clinical responses. If true, that is big news for me.
Reasoning
I would assume that Dr. BP's extremely sensitive companion assays allow him to detect the presence of leronlimab in the blood samples he's receiving from both trials. But even if that's not possible, it is probably safe to assume that Dr. BP can easily see evidence of leronlimag's MOA in the samples he is receiving. In short, he knows who is receiving the drug, and who is receiving placebo.
Many of us have noticed and commented on the apparent confidence being expressed by Dr. NP, Dr. BP and Dr. JL in recent calls and videos. Now, I've been operating under the assumption that, as a group, they were only able to access the lab results. And on that basis, I was happy they were confident with the good labs, but I've been concerned that they could not know if the good labs were actually correlated to favorable clinical results -- especially important for the P2 Mild-Moderate trial.
If Rockleo's second statement is true, then Dr. NP knows:
A. Which patients are receiving leronlimab (from Dr. BP)
B. How each patient receiving leronlimab is reacting on a clinical basis
If true, this ability provides somewhat of an "unblinded" preview of the trial outcomes. And if true, Dr. NP maybe has a better sense (than I assumed) of how these trials will end, and what the general chances are that leronlimab will be approved by the FDA for COVID, for each indication.
So, this is what I am trying to get confirmation of:
As sponsor, is Dr. NP able to see the clinical status of each patient and their corresponding labs?
Thanks in advance for any input.
In the two posts linked directly below, iHub board member Rockleo, who I believe might be a doctor and may have experience running clinical trials, has stated two facts:
Links
https://investorshub.advfn.com/boards/read_ms...=156094612
https://investorshub.advfn.com/boards/read_ms...=156094867
Facts
1. Dr. BP can view the labs. Dr. BP can absolutely can tell which patients are getting what.
My Comment: This is not new information and many of us (myself included) have authored posts indicating that Dr. BP very likely knows exactly which trial participants are receiving leronlimab -- and which are not.
2. As sponsor, Dr. NP is able to see the clinical status of the patients and their corresponding labs. And he is able to confirm if good or great results are being translated into clinical improvements in the patients.
My Comment: This is part I was not formerly aware of -- and it was specifically what I was asking about in my first post. I did not know that Dr. NP (or anyone else for that matter) was in a position to cross-reference each participant's labs -- against their clinical responses. If true, that is big news for me.
Reasoning
I would assume that Dr. BP's extremely sensitive companion assays allow him to detect the presence of leronlimab in the blood samples he's receiving from both trials. But even if that's not possible, it is probably safe to assume that Dr. BP can easily see evidence of leronlimag's MOA in the samples he is receiving. In short, he knows who is receiving the drug, and who is receiving placebo.
Many of us have noticed and commented on the apparent confidence being expressed by Dr. NP, Dr. BP and Dr. JL in recent calls and videos. Now, I've been operating under the assumption that, as a group, they were only able to access the lab results. And on that basis, I was happy they were confident with the good labs, but I've been concerned that they could not know if the good labs were actually correlated to favorable clinical results -- especially important for the P2 Mild-Moderate trial.
If Rockleo's second statement is true, then Dr. NP knows:
A. Which patients are receiving leronlimab (from Dr. BP)
B. How each patient receiving leronlimab is reacting on a clinical basis
If true, this ability provides somewhat of an "unblinded" preview of the trial outcomes. And if true, Dr. NP maybe has a better sense (than I assumed) of how these trials will end, and what the general chances are that leronlimab will be approved by the FDA for COVID, for each indication.
So, this is what I am trying to get confirmation of:
As sponsor, is Dr. NP able to see the clinical status of each patient and their corresponding labs?
Thanks in advance for any input.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼